文献速递呼吸道感染呼吸危重症与机械通气

阿米卡星磷霉素吸入系统辅助治疗革兰阴性呼吸机相关性肺炎的随机试验:IASIS试验

A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
PubMed 文献 · Chest · 2016-11-24

本研究为随机双盲安慰剂对照2期试验,纳入143例革兰阴性菌呼吸机相关性肺炎患者,在标准治疗基础上加用阿米卡星/磷霉素雾化吸入或安慰剂,每日两次共10天。

要点

  • AFIS组第3和7天气管培养阳性率显著低于安慰剂组。

核心结论

  • 在革兰阴性VAP患者中,AFIS辅助治疗虽减少细菌负荷,但未能改善临床结局。

研究设计与样本

  • 随机双盲安慰剂对照平行组2期研究,2013年5月至2016年3月进行,共随机143例患者(AFIS组71例,安慰剂组72例)。

主要发现

  • AFIS组第3和7天气管培养阳性显著少于安慰剂组。

关键数值与推荐

  • AFIS剂量为300 mg阿米卡星/120 mg磷霉素,每日两次雾化吸入,持续10天(或至拔管若<10天)。
  • 主要疗效终点为随机治疗期间CPIS较基线的变化,分析限于微生物学证实基线革兰阴性菌感染的患者亚组。

临床怎么用

  • 不推荐常规使用AFIS辅助治疗革兰阴性VAP以改善临床结局。
  • AFIS可减少气管细菌负荷,但需权衡缺乏临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical failures in ventilator-associated pneumonia (VAP) caused by gram-negative bacteria are common and associated with substantial morbidity, mortality, and resource utilization. METHODS: We assessed the safety and efficacy of the amikacin fosfomycin inhalation system (AFIS) for the treatment of gram-negative bacterial VAP in a randomized double-blind, placebo-controlled, parallel group, phase 2 study between May 2013 and March 2016. We compared standard of care in each arm plus 300 mg amikacin/120 mg fosfomycin or placebo (saline), delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System (PARI GmbH). The primary efficacy end point was change from baseline in the Clinical Pulmonary Infection Score (CPIS) during the randomized course of AFIS/placebo, using the subset of patients with microbiologically proven baseline infections with gram-negative bacteria. RESULTS: There were 143 patients randomized: 71 to the AFIS group, and 72 to the placebo group. Comparison of CPIS change from baseline between treatment groups was not different (P = .70). The secondary hierarchical end point of no mortality and clinical cure at day 14 or earlier was also not significant (P = .68) nor was the hierarchical end point of no mortality and ventilator-free days (P = .06). The number of deaths in the AFIS group was 17 (24%) and 12 (17%) in the placebo group (P = .32). The AFIS group had significantly fewer positive tracheal cultures on days 3 and 7 than placebo. CONCLUSIONS: In this trial of adjunctive aerosol therapy compared with standard of care IV antibiotics in patients with gram-negative VAP, the AFIS was ineffective in improving clinical outcomes despite reducing bacterial burden. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969799; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kollef MH, Ricard JD, Roux D, et al. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial. Chest. 2016. PMID: 27890714. doi:10.1016/j.chest.2016.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。